Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (KAP)

This Phase II randomised, controlled clinical trial (n=70) will compare ketamine-assisted psychotherapy (KAP) to ketamine administered without psychotherapy (KET) for the treatment of major depressive disorder (MDD).

The study, conducted by the Icahn School of Medicine at Mount Sinai in New York, aims to investigate the efficacy of combining psychotherapy with ketamine treatment compared to ketamine alone. Participants, who must be adults aged 18-90 with MDD, will be randomly assigned to either the KAP or KET group in a 1:1 ratio. Both groups will receive treatment over a four-week period.

The researchers will measure depression severity, wellness, neurocognitive functioning, and other parameters at baseline, immediately after the treatment period, and during an 8-week follow-up.

This Phase II trial seeks to determine whether the addition of psychotherapy to ketamine treatment provides enhanced benefits for patients with depression. The study is expected to run from August 2024 to August 2027, potentially offering new insights into optimising ketamine-based interventions for MDD.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Icahn School of Medicine at Mount Sinai
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.